Navigation Links
Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
Date:5/19/2009

pcoming American Society of Clinical Oncology Annual Meeting to be held from May 29 to June 2, 2009 in Orlando, Florida.

In April 2009, CTI began a rolling submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). CTI expects to complete the submission this quarter and will request priority review, which if granted could lead to an approval decision from the FDA in Q4 2009.

Pixantrone is also now available in Europe on a named-patient basis.

About Pixantrone

Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities without sacrificing anti-cancer activity. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
2. Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
3. New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
4. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
5. Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
8. Tanning and Excessive Sun Exposure Can Cause Severe Damage to Eyes
9. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
10. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
11. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Tronics, a ... Sales & Marketing Director. , With more than 25 years of experience ... reinforcing Tronics’ business development activities worldwide. He brings to the company his strong ...
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
(Date:7/30/2015)... ... ... of its 2015 growth plan and as a follow up to the recently announced expansion ... is pleased to announce that it has begun construction on a new Microbiological Laboratory. The ... strictly dedicated to basic USP 51, USP 61, and USP 62 testing specific to raw ...
(Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
Breaking Biology Technology:Tronics appoints Francois Vieillard as Sales and Marketing Director 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... ... of surrogacy. West Coast Surrogacy, Inc. founder/director Amy Kaplan, an expert in reproductive ... carrier. , ... December 29, 2009 -- Children – they’re everywhere, especially during the holidays. A chubby ...
... , , , , , , , ... provider of biopharmaceutical products in China, announced today,that it has filed ... a human clinical trial for its vaccine,against human enterovirus 71 (EV ... first clinical trial application for HFMD vaccine,submitted in China. , ...
... , TSX symbol: SBS , CALGARY, ... an update today on its progress on plant-produced Apo ... between Pfizer Inc. and The Medicines Company, of Parsippany, ... exclusive rights to Pfizer,s Apo AI(Milano) program is a ...
Cached Biology Technology:Is Your New Year's Resolution to Overcome Infertility and Create a Family? A Reputable Surrogacy Agency Can Make 2010 Your Year 2Is Your New Year's Resolution to Overcome Infertility and Create a Family? A Reputable Surrogacy Agency Can Make 2010 Your Year 3Is Your New Year's Resolution to Overcome Infertility and Create a Family? A Reputable Surrogacy Agency Can Make 2010 Your Year 4Is Your New Year's Resolution to Overcome Infertility and Create a Family? A Reputable Surrogacy Agency Can Make 2010 Your Year 5Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 2Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 3Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease 4SemBioSys updates progress on Apo AI(Milano) 2SemBioSys updates progress on Apo AI(Milano) 3
(Date:7/31/2015)... 2015 La 10 th International Conference on ... BGI del 22 al 25 de octubre de 2015 en ... la conferencia celebra su décimo aniversario. Desde su inauguración en ... las reuniones anuales más influyentes del mundo en el campo ... entusiastas y mejores a nivel científico. ICG-10 ...
(Date:7/31/2015)... SHENZHEN, China , July 31, 2015 The ... ) will be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th ... become one of the world,s most influential annual meetings in ... enthusiastic, and enjoyable scientific gatherings. ICG-10 focuses ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... delivery techniques, researchers at Duke University are getting closer ... needed in the body. Performing tissue repair with ... factor proteins -- a task that is very expensive ... within a body. In a new study, however, Duke ...
... Atlantic Ocean from Africa and were likely domesticated many ... to a team of scientists who studied bottle gourd ... ancestry. "Beginning in the 1950s we thought that ... Logan Kistler, post-doctoral researcher in anthropology, Penn State. "However, ...
... hearts need rhythm...even before they have blood to pump. ... when making baby hearts," said Mary Kathryn Sewell-Loftin, a ... engineers, scientists and clinicians attempting to grow replacement heart ... article published last month in the journal Biomaterials ...
Cached Biology News:Regenerating orthopedic tissues within the human body 2Regenerating orthopedic tissues within the human body 3Frequent flyers, bottle gourds crossed the ocean many times 2Baby hearts need rhythm to develop correctly 2Baby hearts need rhythm to develop correctly 3Baby hearts need rhythm to develop correctly 4
Human Kallikrein 1 MAb (Clone 323803) Protein Family: Serine Proteases...
... (HSC) are well-characterized tissue-specific stem cells that ... for the life-long maintenance of the hematopoietic ... in adult bone marrow where hematopoiesis is ... found in cord blood, fetal liver, adult ...
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
Monoclonal 8C2.1 is specific for Bunyavirus G1 as tested by neutralization, immunoprecipitation and immunobinding assays....
Biology Products: